Impact of obesity on the use of antipsychotic drugs in the adult population attended in several primary care centers

Abstract

Introduction. We describe the association between the obesity and the use of antipsychotic drug (APD) in patients attended by five primary care teams.

Methods. Multicenter-retrospective design, carried out between July 2004 and June 2005, in patients who consumed APD treatment. A Body Mass Index (BMI) >29 kg/m2 was considered obesity. The main measurements were: consumption of APD, generals (gender and age), comorbidities and clinical parameters. Regression-logistic analysis and ANCOVA (Bonferroni-adjustment) were applied to correct the model.

Results. From a total of 42,437 attended patients (mean age: 50.9 (SD: 17.8) years; women: 59.9%; with obesity: 27.3% [confidence interval [CI] 95%: 26.9-27.7]), the 1.3% received APD treatment (typical: 48.8%; atypical: 51.2%; p=not significant). In the logistic-model the obesity was related with the ADP use (odds ratio [OR]: 1.5, CI: 1.3-1.8), hypertension (OR: 2.4; CI:2.2-2.5), diabetes (OR: 1.4; CI: 1.31.5) and dyslipidemia (OR: 1.3; CI: 1.2-1.4); p=0,000. The adjusted BMI, in presence of APD, was 27.8 kg/m2 vs. 27.4 kg/m2; p=0,002.

Conclusions. Obesity was associated with the use of APD and with the presence of hypertension, diabetes and dyslipidemia. Differences could not be observed between the use of typical or atypical APD.